For example, in the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy trials, the percentage of patients in each lesion size category (≤3, >3 to 6, >6 to 9, and >9 disc areas) was given. To analyze this data, we used the midpoint value within each lesion size category (ie, 1.5, 4.5, and 7.5 disc areas, respectively); we used 9 disc areas for the largest lesions because data on larger lesion sizes were not available. The mean lesion size at a given point was estimated by taking a weighted average of the midpoint lesion size of each category. For example, at baseline in the Verteporfin in Photodynamic Therapy trial, 29%, 50%, 17%, and 2% of the patients were in the less than or equal to 3, greater than 3 to 6, greater than 6 to 9, and greater than 9 disc area categories, respectively. Therefore, the mean lesion size of the Verteporfin in Photodynamic Therapy trial at baseline was (1.5 × 29%) + (4.5 × 50%) + (7.5 × 17%) + (9 × 2%) = 4.1 disc areas. For the VEGF Inhibition Study in Ocular Neovascularization trial, 2 sets of data were used because the trial actually consisted of 2 concurrent studies. For the Phase 3b, Multicenter, Randomized, Double-masked, Sham Injection–controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization with or without Classic Choroidal Neovascularization Secondary to AMD Study, the final total lesion size was not provided, thus we estimated that the proportion of lesion consisting of choroidal neovascularization was similar at the initial and final points.